Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer, Chemotherapy Effect
Phase PHASE3
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

According to the latest data from the World Health Organization's International Agency for Research on Cancer (IARC) for 2020, breast cancer has been the most prevalent cancer with 2.26 million new cases. Among Chinese breast cancer patients, approximately 60% are hormone receptor (HR) positive, and 80% have early-stage breast cancer. For HR-positive, human epidermal growth factor receptor-2 (HER2) negative breast cancer patients, the first peak of recurrence is about 2-3 years after surgery, especially for patients with high-risk clinical and/or pathological features. Therefore, adjuvant therapy is essential to reduce recurrence during this period. Capecitabine is an anti-metabolite fluoropyrimidine deoxynucleoside carbamate that can be converted to fluorouracil (5-Fu) in vivo. Studies have shown that patients with HR-positive HER2-negative breast cancer with high-risk factors may benefit from postoperative adjuvant capecitabine therapy as well as patients with triple-negative breast cancer. Therefore, we assumed that additional capecitabine may reduce the reccurence of breast cancer in patients with high-risk factors. This trial is an open, single-arm clinical trial designed to investigate the effect of additional adjuvant capecitabine therapy on recurrence and survival in HR-positive HER2-negative breast cancer patients with high-risk factors.

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Capecitabine — capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.

Primary Outcomes

  • disease free survival (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-03-15
Completion: 2029-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Wei Tian, Doctor
+86 13777825246
denyiweit@zju.edu.cn
Jianan Wang, Doctor
the Second Affiliated Hospital of Zhejiang Univercity School of Medicine
Weilin Wang, Doctor
the Second Affiliated Hospital of Zhejiang Univercity School of Medicine
Interventions
  • Drug: Capecitabine — capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
Study Locations (1 sites)
the Second Affiliated Hospital of Zhejiang Univercity School of Medicine, Hanzhou, Zhejiang China
Eligibility Criteria
Inclusion Criteria: * Female, age 18-70 years. * Completed radical breast cancer surgery with confirmed pathology suggested primary invasive breast adenocarcinoma, ER and/or PR positive (defined as positive cells \>1%) and HER2 negative (defined as HER2 immunohistochemistry 2+ or less and FISH negative). * Definition of high-risk factors: 4 or more positive axillary lymph nodes; 1-3 positive axillary lymph nodes with primary tumor ≥ 5 cm or histologic grade 3 or ki67 ≥ 20%; or residual lesions despite neoadjuvant chemotherapy. * No prior treatment for present breast cancer onset. * ECOG physical status score 0 to 1 * Hematological examination before treatment should meet: white blood cell count (WBC) ≥ 4.0×10\^9/L, neutrophil count (ANC) ≥ 1.5×10\^9/L, platelet count (PLT) ≥ 100×10\^9/L; hemoglobin (Hb) ≥ 90g/L; AST (sGOT), ALT (sGPT) ≤ 1.5 times the normal value upper limit, creatinine ≤ 1.5 times the upper limit of normal value, total bilirubin ≤ 1.5 times the upper limit of normal value. * No serious impairment of heart, liver, kidney and other important organ functions. Exclusion Criteria: * Unwilling or unable to use an acceptable method of contraception for up to and including 8 weeks after the final dose of the test drug. * Women during pregnancy and breastfeeding after pregnancy. * Women with proven distant metastases of breast cancer. * Patients with proven sensory or motor nerve disease. * Definite cardiovascular disease, severe co-morbidity or active infection, including known HIV infection. * Patients who need long-term anticoagulant drugs for cardiovascular or thrombotic diseases. * History of other tumors. * Allergic to the study drug or its excipients, etc.
Conditions Breast Cancer, Breast Hypertrophy
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The main purpose of the project is to validate patient reported outcomes measures (PROMs) in reconstructive breast surgery. BREAST-Q will be evaluated for Swedish and Sweden.Hospital Anxiety and Depression Scale (HADS), EuroQol 5D (EQ5D), and SF-36 will be validated for reconstructive breast surgery. In addition, the complication classification system according to Clavien-Dindo will be validated for reconstructive breast surgery.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Breast reconstruction — Breast reconstruction after breast cancer.
  • Procedure: Breast reduction — Breast reduction due to breast hypertrophy.

Primary Outcomes

  • Validation and reliability of BREAST-Q for Sweden (Pre-operatively)
  • Validation and reliability of BREAST-Q for Sweden (5 years postoperatively)
  • Validation and reliability of EuroQol-5 dimensions, 3 levels for reconstructive breast surgery (Pre-operatively)
  • Validation and reliability of EuroQol-5 dimensions, 3 levels for reconstructive breast surgery (5 years postoperatively)
  • Validation and reliability of Hospital Anxiety and Depression scale (HADS) for Reconstructive breast surgery (Pre-operatively)
  • Validation and reliability of Hospital Anxiety and Depression scale (HADS) for Reconstructive breast surgery (5 years postoperatively)
  • Validation and reliability of RAND-36 for reconstructive breast surgery (Pre-operatively)
  • Validation and reliability of RAND-36 for reconstructive breast surgery (5 years postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-06-21
Completion: 2027-12-21
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Contact Information
Study Contact:
Emma Hansson, MD, PhD
+46313421000
emma.em.hansson@vgregion.se
Emma Hansson, PhD
+46 31 342 10 00
emma.hansson.2@gu.se
Sahlgrenska university hospital
Interventions
  • Procedure: Breast reconstruction — Breast reconstruction after breast cancer.
  • Procedure: Breast reduction — Breast reduction due to breast hypertrophy.
Study Locations (1 sites)
Sahlgrenska university hospital, Gothenburg, 413 45 Sweden
Eligibility Criteria
Inclusion Criteria: * Women who have had or will have reconstructive breast surgery in Sahlgrenska university hospital. Exclusion Criteria: * Do not understand Swedish.
Conditions Congenital Diaphragmatic Hernia
Phase PHASE4
Enrollment 600
Locations 19 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine if de-implementation of inhaled nitric oxide (iNO) in the post-natal resuscitation/stabilization phase affects the composite outcome of extracorporeal life support (ECLS) use and/or mortality, as well as ECLS use, mortality, and/or oxygenation in congenital diaphragmatic hernia (CDH) newborns and to establish the cost-effectiveness of de-implementing iNO as a therapy in the postnatal resuscitation/stabilization phase of CDH management, which will be assessed as the incremental health system costs (savings) per prevented ECLS use and/or death.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Inhaled Nitric Oxide (iNO) use — The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
  • Other: De-implementation of Inhaled Nitric Oxide (iNO) use — The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).

Primary Outcomes

  • Number of participants who require Extracorporeal Life Support (ECLS) and/or who die prior to discharge (from birth through hospital discharge (up to 12 months from birth))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-11-01
Completion: 2031-04-30
Eligibility
Age: 0 Months and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center, Houston
Collaborators: University of Tennessee & LeBonheur Children's Hospital (UT-LBCH), Children's Hospital of Orange County, Medical University of South Carolina Children's Health (MUSC), University of Michigan & CS Mott Children's Hospital (UM-CSMott), Randall Children's Hospital-Portland (RCH), Stanford University & Lucile Packard Children's Hospital (Stanford-LPCH), Rady Children's Hospital, San Diego, Boston Children's Hospital, Indiana University & Riley Children's Hospital (IU-RiCH), Norton Children's Hospital, University of Utah & Primary Children's Hospital (Utah-PCH), University of Washington & Seattle Children's Hospital (UW-SCH), University of Alabama & Children's Hospital of Alabama (UAB-CoA), University of Arkansas, Vanderbilt University Medical Center, University of Southern California & Children's Hospital Los Angeles (USC-CHLA), Emory University & Children's Healthcare of Atlanta (CHOA), Children's Hospital Colorado
Principal Investigators:
  • Matthew Harting, MD, MS, FACS (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center, Houston
Contact Information
Study Contact:
Matthew Harting, MD, MS, FACS
(713) 500-7398
Matthew.T.Harting@uth.tmc.edu
Ashley Ebanks
(832) 325-7234
Ashley.Harmon@uth.tmc.edu
Scott Anderson, MD
Scott.Anderson@childrensal.org
University of Alabama & Children's Hospital of Alabama (UAB-CoA)
Interventions
  • Drug: Inhaled Nitric Oxide (iNO) use — The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
  • Other: De-implementation of Inhaled Nitric Oxide (iNO) use — The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
Study Locations (19 sites)
University of Alabama & Children's Hospital of Alabama (UAB-CoA), Birmingham, Alabama 35233 United States
University of Arkansas & Arkansas Children's Hospital (UA-ACH), Little Rock, Arkansas 72202 United States
University of California-Irvine & Children's Hospital of Orange County (UC-CHOC), Irvine, California 92868 United States
University of Southern California & Children's Hospital Los Angeles (USC-CHLA), Los Angeles, California 90027 United States
Stanford University & Lucile Packard Children's Hospital (Stanford-LPCH), Palo Alto, California 94304 United States
University of California, San Diego & Rady Children's Hospital (UCSD-Rady), San Diego, California 92123 United States
University of Colorado & Children's Hospital of Colorado (CU-CHC), Aurora, Colorado 80045 United States
Emory University & Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia 30322 United States
Indiana University & Riley Children's Hospital (IU-RiCH), Indianapolis, Indiana 46202 United States
University of Louisville & Norton Children's Hospital (UL-NCH), Louisville, Kentucky 40202 United States
Eligibility Criteria
Inclusion Criteria: * Postnatal, live born neonates with CDH a. Presence of associated or additional anomalies is acceptable for inclusion * Bochdalek hernia location (right or left) * Diagnosed prior to 1 month of life * Born within or transferred to (within 1 week of life) a CDHSG member center participating in the trial Exclusion Criteria: * CDH diagnosis after 1 month of age * Morgagni diaphragmatic hernia (central / anterior-medial diaphragmatic defect location) * Transferred to a CDH Study Group (CDHSG) member center after 1 week of life * Patients without potential access to iNO
Conditions Type 1 Diabetes
Phase PHASE2
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Type 1 diabetes (T1D) is caused by the destruction of insulin-producing cells by effector T cells (Teffs), due to a deficiency of regulatory T cells (Tregs). Ciclosporin effectively blocks the Teffs and controls diabetes, but cannot be considered as a long-term treatment. Low-dose interleukin-2 (ld IL-2) activates and expands Tregs in humans. Hence, Ld IL-2 in patients in whom the autoimmune process was blocked early by a short treatment (2 months) of cyclosporine should restore immune homeostasis and maintain some insulin production over the long term.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Cyclosporin — • Ciclosporin: 5mg/kg, twice a day, oral, between Day 1 and Day 60
  • Drug: ILT101 — • ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354.
  • Drug: Placebo — • Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.

Primary Outcomes

  • Treg variation (From Day 63 to Day 67)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-09-21
Completion: 2027-11-29
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Collaborators: Iltoo Pharma
Principal Investigators:
  • David Klatzmann, MD, Ph.D (STUDY_DIRECTOR) - APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS
  • Agnès Hartmann, MD, Ph.D (PRINCIPAL_INVESTIGATOR) - APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS
Contact Information
Study Contact:
David Klatzmann, MD, Ph.D
01 42 17 74 61
david.klatzmann@sorbonne-universite.fr
Roberta Lorenzon, MD
01 42 17 65 16
roberta.lorenzon@sorbonne-universite.fr
Roberta Lorenzon, MD
roberta.lorenzon@sorbonne-universite.fr
Lorenzon Roberta
Interventions
  • Drug: Cyclosporin — • Ciclosporin: 5mg/kg, twice a day, oral, between Day 1 and Day 60
  • Drug: ILT101 — • ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354.
  • Drug: Placebo — • Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.
Study Locations (1 sites)
Lorenzon Roberta, Paris, 75013 France
Eligibility Criteria
Inclusion Criteria: * • Age at inclusion between ≥ 16 years old (Tanner 5 pubertal stage) and ≤ 45 years old * Type 1 diabetes according to ADA criteria, with at least 1 positive autoantibody among the following: anti-islet, anti-GAD, anti-IA2, anti-ZnT8 and anti-insulin. * Diagnosis ≤ 3 months * No acid ketosis * No weight loss \> 10% OR with fasting C-peptide ≥ 0.1 nmol/L (after a period of ≥ 15 days following the initiation of insulin therapy * Absence of clinically significant biological abnormalities on hematological, biochemical, hepatic, renal and thyroid tests. * No documented history of heart disease, no family history of sudden death, AND normal ECG. * Effective contraception in men and women of childbearing potential \> 2 weeks prior to first administration of the investigational drug and throughout the treatment period (if sexually active). Specifically for women of childbearing age and sexually active, they must use an effective contraceptive method (Pearl Index \< 1). The following methods are acceptable: oral hormonal contraceptives, injectable, or implanted (with the exception of oral minipills: i.e. low doses of gestagens which are not acceptable (lynestrenol and norestisteron), intrauterine contraceptives (e.g. progestin-release systems)), * Free, informed and written consent, signed by the patient and the investigator, prior to any examination required by the trial. If the patient is a minor, the signatures of both parents and of the child will be collected (or the legal representative if only one parent is alive). Exclusion Criteria: * Known contraindications to IL2 treatment: * Hypersensitivity to the active substance or to one of the excipients. * Signs of active infection requiring antibiotics * Documented history of clinical autoimmune disease * Oxygen saturation ≤ 90% * Existence of a serious dysfunction in a vital organ * History of organ allograft, * Known contraindications to treatment with cyclosporine * Presence of unauthorized treatment, i.e. cytotoxic drugs, products known for their impact on blood glucose levels or for their interactions with the treatments under trial * Patients who have received anti-diabetic treatment other than insulin for more than 3 consecutive months. * Anti-thyroperoxidase positive and abnormal TSH and T4 at inclusion * Anti-transglutaminase positive at inclusion * EBV viral load \> 2000 IU/ml * CMV viral load \> 400 IU/ml * HBV, HCV or HIV infection * Lymphopenia ≤ 1000/ mm3 * Presence or history of cancer that has been cured for less than five years, except in situ cervical or basal cell carcinoma in early stage management, * Participation in other intervention research involving humans \< 3 months, * Pregnant or breastfeeding women * Lack of social security affiliation (as a beneficiary or assignee) * Vaccination with live attenuated virus during the last 4 weeks before the start of the experimental treatment and during the entire treatment phase. * Patient with active SARS-CoV-2 infection * Patient with chronic respiratory disease * Subject under legal protection (such as tutorship, curatorship, or judicial safeguard) * Subject hospitalized without consent, unable to express consent or deprived of liberty
Conditions Breast Cancer, Treatment Side Effects, A...
Phase EARLY_PHASE1
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy (GC 101 TIL) in patients with advanced breast cancer. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Tumor Infiltrating Lymphocytes (TIL) — Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.

Primary Outcomes

  • Adverse Events (AE) (6 months)
  • Objective Response Rate (ORR) (Up to 36 months)
  • Disease Control Rate (DCR) (Up to 36 months)
  • Duration of Response (DOR) (Up to 36 months)
  • Progression-Free Survival (PFS) (Up to 36 months)
  • Overall Survival (OS) (Up to 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2021-11-19
Completion: 2027-12-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Juncell Therapeutics
Collaborators: Shanghai 10th People's Hospital
Contact Information
Study Contact:
GC Clinical
086-18001759113
clinicaltrials@juncell.com
Qing Xu
xuqingmd@aliyun.com
Shanghai Tenth People's Hospital
Interventions
  • Biological: Tumor Infiltrating Lymphocytes (TIL) — Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study Locations (1 sites)
Shanghai Tenth People's Hospital, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. Age: 18 years to 75 years; 2. Histologically diagnosed as primary/relapsed/metastasized breast cancer; 3. Expected life-span more than 3 months; 4. Karnofsky≥60% or ECOG score 0-2; 5. Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available. 6. Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated; 7. At least 1 evaluable tumor lesion; 8. Hematology and Chemistry(within 7 days prior to enrollment): * Absolute count of white blood cells≥2.5×10\^9/L; * Absolute count of neutropils≥1.5×10\^9/L; * Absolute count of lymphocytes ≥0.7×109/L; * Platelet count≥100×10\^9; * hemoglobin≥90 g/L; * Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days); * International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days); * Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min; * Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN); * Totol bilirubin≤1.5×ULN; 9. no absolute or relative contraindications to operation or biopsy; 10. Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 1 year after the completion of lymphodepletion; 11. Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy and biologics must cease 28 days before obtaining TILs; 12. Be able to understand and sign the informed consent document; 13. Be able to stick to follow-up visit plan and other requirements in the agreement. Exclusion Criteria: 1. Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment; 2. Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%; 3. Significant cardiovascular anomalies according to any of the following definition: New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block, etc. 4. Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive; 5. Severe physical or mental diseases; 6. Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection); 7. Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy; 8. History of allergy to chemical compound consisting of chemical and biologic substances resembling cell therapy; 9. Having received immunotherapy and developed irAE level greater than Level 3; 10. Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded); 11. Females in pregnancy or lactation; 12. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy; 13. Researchers considering the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.
Conditions Breast Cancer
Phase NA
Enrollment 712
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Neoadjuvant chemotherapy (NACT) is increasingly used in breast cancer. The best proof of NACT efficacy is pathological complete response (pCR), i.e. the absence of invasive tumour on post-NACT surgical histopathology. While it is known that physical exercise can help patients to better tolerate and complete often harsh cancer treatments, it is an emerging area of research to understand if and how exercise exerts anti-tumour effects and improves oncological outcomes. The main aim of the Neo-ACT trial is to examine if a physical exercise intervention during NACT can increase pCR rates in breast cancer. Secondary aims are residual cancer burden, radiological tumour response, patient-related outcomes (health-related quality of life, physical activity), physiological outcomes (muscle strength, cardiorespiratory fitness), cancer treatment-related toxicities (cognitive dysfunction, chemotherapy completion rates) and long-term sick leave. Furthermore, the trial will explore how physical exercise affects anti-tumoral mechanisms inherent to therapy or host by hypothesis-generating translational analyses. 712 patients with primary invasive breast cancer will be randomized to either a supervised intervention of high-intensity interval and resistance training during NACT, supported by an exercise app, or to usual care, and followed for two years. Physical activity is meticulously tracked. By offering patients active involvement, the trial contributes strongly to the concept of personalized medicine.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Physical training — Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).

Primary Outcomes

  • Pathological complete response (5-6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-11-09
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 712 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Principal Investigators:
  • Jana de Boniface (PRINCIPAL_INVESTIGATOR) - Karolinska Institutet
Contact Information
Study Contact:
Jana de Boniface
+46702472305
jana.de-boniface@ki.se
Cecilia Haddad Ringborg
cecilia.haddad.ringborg@ki.se
Eva Zopf
Cabrini Health
Interventions
  • Behavioral: Physical training — Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).
Study Locations (13 sites)
Cabrini Health, Melbourne, Australia
Helsinki University Hospital, Helsinki, Finland
Turku University Hospital, Turku, Finland
Karolinska University Hospital, Stockholm, Stockholm County 17176 Sweden
Sahlgrenska University Hospital, Gothenburg, Sweden
Skaraborgs sjukhus, Lidköping, Sweden
Capio St Görans Hospital, Stockholm, Sweden
Southern General Hospital, Stockholm, Sweden
Sundsvall Hospital, Sundsvall, Sweden
Umeå University Hospital, Umeå, Sweden
Eligibility Criteria
Inclusion Criteria: * Patients with primary invasive breast cancer cT1-T3 cN0-2 * Full tumour biology available before initiation of NACT * Oral and written consent * Age ≥ 18 years Exclusion Criteria: * Pregnancy or breast-feeding * Bilateral invasive breast cancer * The presence of musculoskeletal, neurological, respiratory, metabolic or cardiovascular conditions that may prevent safe completion of the exercise demands of the study * Currently performing equal to or more than 150 mins of moderate to high intensity aerobic exercise and 2 sessions per week of moderate intensity resistance exercise
Conditions Mild Cognitive Impairment in Middle-aged...
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A mild cognitive impairment was observed in 50% of cochlear implant candidates aged 65 years and over, compared to 5-19% in general population. No studies analysed cognition in patients younger than 65 years. The aim of our study was to compare cognitive function between patients with severe and profound hearing loss and patients with normal hearing in patients aged 45 to 64 years.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cognitive and audiometry evaluation — For both Patients and controls: * Cognitive functions evaluation * Tonal and vocal audiometry * Self questionnaires

Primary Outcomes

  • Evaluation of Mini Mental State Examination to access cognitive impairment in patients with severe to profound hearing loss compare to subjects with normal hearing (1 day)
  • Evaluation of Trail making tests (TMT) A et B to evaluate executive functions in patients with severe to profound hearing loss compare to subjects with normal hearing (1 day)
  • Evaluation of "Fluences verbales sémantique et phonémique" to evaluate linguistic skills in patients with severe to profound hearing loss compare to subjects with normal hearing (1 day)
  • Evaluation of 16-item Free and Cue Selective Recall Test (RLRI/16) to evaluate episodic memory in patients with severe to profound hearing loss compare to subjects with normal hearing (1 day)
  • Evaluation of Digit Symbol Substitution Test to evaluate psychomotor speed and executive functions, executive functions in patients with severe to profound hearing loss compare to subjects with normal hearing (1 day)
  • Evaluation of Instrumental activities of daily living scale to evaluate the level of dependence of dependence of the subjects in patients with severe to profound hearing loss compare to subjects with normal hearing (1 day)
  • Evaluation of Cognitive Complaint Questionnaire to evaluate Cognitive assessment in patients with severe to profound hearing loss compare to subjects with normal hearing (1 day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-05-24
Completion: 2027-05-24
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Principal Investigators:
  • Isabelle Dr MOSNIER, MD (PRINCIPAL_INVESTIGATOR) - Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
Isabelle Dr MOSNIER, MD
142162612
isabelle.mosnier@aphp.fr
Nassima SCHMOLL
142163089
nassima.schmoll@aphp.fr
Isabelle Dr MOSNIER, MD
142162612
isabelle.mosnier@aphp.fr
Centre de Recherche en Audiologie (CReA) - Groupe Hospitalier Pitié-Salpêtrière
Interventions
  • Behavioral: Cognitive and audiometry evaluation — For both Patients and controls: * Cognitive functions evaluation * Tonal and vocal audiometry * Self questionnaires
Study Locations (1 sites)
Centre de Recherche en Audiologie (CReA) - Groupe Hospitalier Pitié-Salpêtrière, Paris, 75013 France
Eligibility Criteria
Inclusion Criteria: * Cases: Patients aged between 45 to 64 years with severe to profound bilateral post-lingual sensorineural hearing loss with a maximum intelligibility of 70% (disyllabic words) in free-field silence with hearing aids at 60 dB SPL, current in french * Controls: normal hearing subjects matched on age, sex and education level Exclusion Criteria: * Associated disability that prevents the tests from being performed * Past and current history of neurological and psychiatric disorders including meningitis * Psychotropic drug treatment * Vulnerable subject
Conditions Major Depressive Disorder
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a quasi-experimental, multi-site cluster controlled clinical trial design with two intervention arms--Treatment As Usual (TAU) and an Integrated Care Pathway (ICP). Eligible participants are between the ages of 13 and 18, who present to community mental health agencies with depressive symptoms as the primary concern. The primary clinical outcome of interest is the difference between treatment groups in the rate of change of depressive symptoms from baseline to 24-week endpoint as measured by the Mood and Feelings Questionnaire. The secondary outcomes include rate of change of functional improvement, as measured by the Childhood Anxiety and Depression Life Interference Scale, and caregiver-rated internalizing symptoms as rated by the Childhood Behaviour Checklist. This study will also be examining implementation outcomes such as feasibility, fidelity cost and acceptability.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Treatment As Usual — Various typical interventions for adolescents with depression.
  • Other: CARIBOU-2 — Integrated Care Pathway intervention for adolescents with depression.

Primary Outcomes

  • The Mood and Feelings Questionnaire (MFQ) child, long version (Change from baseline to 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-02-01
Completion: 2027-09-30
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre for Addiction and Mental Health
Collaborators: Canadian Institutes of Health Research (CIHR), The Hospital for Sick Children
Principal Investigators:
  • Darren B Courtney, MD (PRINCIPAL_INVESTIGATOR) - University of Toronto
Contact Information
Study Contact:
Darren B Courtney, MD
800-463-2338
dr.courtney.research@gmail.com
Eva Gonzalez Villanueva, Research Coordinator, MPH, MSSW, RSW
800-463-2338
eva.gonzalezvillanueva@camh.ca
Katye Stevens, Research Operations Manager
800-463-2338
Katye.Stevens@camh.ca
Centre for Addiction and Mental Health
Interventions
  • Other: Treatment As Usual — Various typical interventions for adolescents with depression.
  • Other: CARIBOU-2 — Integrated Care Pathway intervention for adolescents with depression.
Study Locations (1 sites)
Centre for Addiction and Mental Health, Toronto, Ontario Canada
Eligibility Criteria
Inclusion Criteria: * Youth is aged 13 to 18 years, inclusive. * Youth and/or their caregiver is expressing that 'depression" (or some synonym) is a concern. * Clinician agrees that depressive symptoms are a treatment target. * Mood and Feelings Questionnaire score is ≥22 at two sequential visits (screening and baseline assessment). * Youth must be new to the site (in past 3 months) or have a period of no treatment for 3 months Exclusion Criteria: * Known or highly suspected presentations of psychotic symptoms that are persistent, affect functioning, and have observable effects on behaviour. * Severe substance use disorder, bipolar disorder, autism spectrum disorder or intellectual disability, severe eating disorder, imminent risk of suicide requiring hospitalization as per judgment of the assessing clinician. * Inability to provide informed consent to the study for any reason * Youth currently in Day Treatment
Conditions Breast Cancer
Phase Not Applicable
Enrollment 2500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to survey how many women have breast implants in the mammography screening population and the effect of implants on the number and type of examinations and on costs.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Mammography screening — Breast screening mammograms use X-rays to look for cancers that are too small to see or feel.

Primary Outcomes

  • Costs (1 year post-operatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-05-12
Completion: 2026-12-31
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: Not specified
Enrollment: 2500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Contact Information
Study Contact:
Emma Hansson, MD,PhD
+46313421000
emma.em.hansson@vgregion.se
Emma Hansson, PhD
+46 31 342 10 00
emma.hansson.2@gu.se
Sahlgrenska university hospital
Interventions
  • Diagnostic Test: Mammography screening — Breast screening mammograms use X-rays to look for cancers that are too small to see or feel.
Study Locations (1 sites)
Sahlgrenska university hospital, Gothenburg, 413 45 Sweden
Eligibility Criteria
Inclusion Criteria: * Women participating in the mammography screening program. Exclusion Criteria: * None
Conditions Atherosclerotic Plaque, Diabetes Mellitu...
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Coronary heart disease (CHD) is a major cause of morbidity, disability, mortality, and health expenditures worldwide. A wealth of studies has demonstrated that people of South Asian ancestry have a higher risk of CHD and particularly premature CHD than most other racial/ethnic groups, and recent research suggests that this risk is higher in Pakistanis than in Indians-the two largest SA groups. Pakistan is the 5th most populous country in the world, and despite these concerning trends, so far there has been a scarcity of large studies evaluating the prevalence of cardiovascular risk factors and subclinical coronary atherosclerosis in young-to-middle-aged Pakistanis. Also, there is currently no cardiovascular risk score specifically tailored to younger Pakistani men and women. The PAKistan Study of prEmature coronary atHerosclerosis in young AdulTs (PAK-SEHAT) aims at addressing these important gaps. PAK-SEHAT is an ongoing prospective cohort study that will enroll 2,000 asymptomatic Pakistani men aged 35 to 60 years and women aged 35 to 65 years from the general population, free of clinically overt cardiovascular disease. Participants will undergo a comprehensive baseline exam including coronary computed tomography angiography, and will be followed for incident events and repeat testing for 5 years. PAK-SEHAT will allow determining the prevalence, severity, determinants, and prognostic significance of early atherosclerosis in apparently healthy young-to-middle-aged Pakistanis. This knowledge can help inform primordial and primary prevention strategies, enhanced cardiovascular risk stratification, and potential plaque-screening approaches in Pakistan, all of which can ultimately help reduce the burden of CHD in the country. In this report investigators describe the rationale, objectives, methods, and discuss the potential implications of the PAK-SEHAT study.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Burden of atherosclerotic plaque assessed via coronary computed tomography angiography (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-03-15
Completion: 2028-11
Eligibility
Age: 35 Years and older
Sex: ALL
Volunteers: true
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tabba Heart Institute
Collaborators: Getz Pharma
Contact Information
Study Contact:
Bashir Hanif, FSCAI
+92-21-36811841
bashir.hanif@tabbaheart.org
Ghazal Peerwani, MSc
+92-21-36811841
ghazal.peerwani@tabbaheart.org
Ghazal Peerwani
ghazal.peerwani@tabbaheart.org
Tabba Heart Institute
Interventions
N/A
Study Locations (1 sites)
Tabba Heart Institute, Karachi, Sindh 74500 Pakistan
Eligibility Criteria
Inclusion Criteria: * Native Pakistani * Men aged 35-60 years \& women aged 35-65 years * Willing to consent to participation Exclusion Criteria: eGFR \< 60 ml/min/1.73m2 Pregnant women History of stroke or MI (CABG or PCI) History of Peripheral arterial disease Weight more than 102 Kg Any active malignancy Known contraindication from contrast used in cardiac CTA Expected migration from residential area within 5 years
Conditions Breast Atypical Ductal Hyperplasia, Brea...
Phase Not Applicable
Enrollment 960
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve prevention strategies, and provide timely intervention for early therapeutic management as needed.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Follow-Up — Undergo follow up
  • Procedure: Physical Examination — Complete physical measurements
  • Other: Questionnaire Administration — Complete questionnaires

Primary Outcomes

  • Time to breast cancer events during study follow up (Up to 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-10-25
Completion: 2035-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 960 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University Comprehensive Cancer Center
Principal Investigators:
  • Sagar D Sardesai, MSPH, PhD (PRINCIPAL_INVESTIGATOR) - Ohio State University Comprehensive Cancer Center
Contact Information
Study Contact:
The Ohio State University Comprehensive Cancer Center
800-293-5066
OSUCCCClinicaltrials@osumc.edu
Sagar D. Sardesai, MSPH, PhD
614-293-6401
Sagar.Sardesai@osumc.edu
Ohio State University Comprehensive Cancer Center
Sagar D. Sardesai, MSPH, PhD
Ohio State University Comprehensive Cancer Center
Interventions
  • Procedure: Follow-Up — Undergo follow up
  • Procedure: Physical Examination — Complete physical measurements
  • Other: Questionnaire Administration — Complete questionnaires
Study Locations (1 sites)
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * Age \>= 18 years * Established in the high risk clinic at OSUCCC- James (includes patients with family history of breast cancer \[BC\], known genetic predisposition, personal history of known atypia/breast lobular carcinoma in situ \[LCIS\], or prior chest wall radiation) * Patients at high risk for BC established in the surgical oncology clinic at Stefanie Spielman Comprehensive Breast Center (SSCBC), with one of the following diagnoses: Atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), sclerosing adenosis (SA), or radial scars (RS) * Able to read and understand English * Able to provide informed consent * Must consent to continued follow-up of medical records during the study period Exclusion Criteria: * Prisoners * Not able to speak and understand English * Known personal history of ductal carcinoma in situ (DCIS) or Invasive BC
Conditions Bariatric Surgery, Hypertension
Phase Not Applicable
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to investigate the effect of bariatric surgery on cardiac function assessed by echocardiography in patients with hypertension.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Procedure: LSG — Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
  • Procedure: RYGB — Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.

Primary Outcomes

  • Changes on left ventricular ejection fraction (LVEF) (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2018-08-01
Completion: 2027-06-30
Eligibility
Age: 17 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Friendship Hospital
Principal Investigators:
  • Rongchong Huang, M.D. (PRINCIPAL_INVESTIGATOR) - Beijing Friendship Hospital
Contact Information
Study Contact:
Rongchong Huang, M.D.
+86-13811039417
rchuang@ccmu.edu.cn
Rongchong Huang, M.D.
+86-13811039417
rchuang@ccmu.edu.cn
Beijing Friendship Hospital, Capital Medical University
Rongchong Huang, M.D.
Beijing Friendship Hospital, Capital Medical University
Interventions
  • Procedure: LSG — Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
  • Procedure: RYGB — Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
Study Locations (1 sites)
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing Municipality 100050 China
Eligibility Criteria
Inclusion Criteria: * 18-70 years old * BMI\>24kg/m2 * Bariatric surgery patients of Beijing Friendship Hospital * History of hypertension and treated with ≥2 antihypertensive drugs for more than 4 weeks * No major barriers to provide written consent Exclusion Criteria: * Secondary hypertension, except because of sleep apnea * cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months * Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases) * Unable to understand or comply with the study procedures